This week in therapeutics




Licensing status

Publication and contact information


Breast cancer

Dedicator of cytokinesis 1 (DOCK1)

Patient sample and mouse studies suggest inhibiting DOCK1 could help prevent breast cancer metastasis. In tumor samples from patients with breast cancer, increased expression of DOCK1 was associated with poor survival in HER2 (EGFR2; ERBB2; neu)-positive and basal breast cancers. In a mouse model for HER2-positive breast cancer, mammary gland-specific knockout of Dock1 decreased primary tumor burden and metastasis to lungs compared with no knockout. In mice injected with HER2-positive breast cancer, small interfering RNA-mediated knockdown of DOCK1 led to decreased metastases compared with no knockdown. Next steps include identifying compounds that block DOCK1 and evaluating them in animal models for cancer.

SciBX 6(17); doi:10.1038/scibx.2013.410
Published online May 2, 2013

Patent application filed; available for licensing from Kyushu University's Intellectual Property Management Center

Laurin, M. et al.
Proc. Natl. Acad. Sci. USA
published online April 16, 2013;
Contact: Jean-François Côté,
Montreal Institute of Clinical Research, Montreal, Quebec, Canada